Bangalore-based Stabicon, which is incubated at Bangalore Bioinnoavtion Centre (BBC), has launched CD4 Shield. The start-up has been working on prevention program for the novel coronavirus (nCOV-19) using the company’s proprietary Zuicel technology. It consists of holistic turmeric active concentrate of curcumin and turmerones with high efficacy under very significant low dose of 1 - 10mg for health and wellness segment. The program is based on regenerative medicine properties and has massive potential for treating pre-metabolic and metabolic syndrome from last 8 years.

During a controlled clinical trial for metabolic syndrome evaluation, the outcome has concluded to be safe and therapeutic. The data is supported by pool of global scientific publication evidence that solubility improved by Zuicel technology on Curcumin and turmerones. The observation was, the technology assists on molecular action in modulating immune system against host specific attack as well as breaking down coronavirus machinery process. This observation led to repurposing of existing innovative solution towards preventive and curative care programme against nCOV outbreak. 

CD4 Shield is developed by Vijay Kumar Ranka and his team. It was launched by Dr AshwathNarayan C N, Deputy Chief Minister and Minister of Electronics, IT, BT and S&T, Government of Karnataka, in presence of Dr K VijayRaghavan, Principal scientific adviser, Government of India.

The use of Zuicel technology on curcumin and turmerones along with cyanocobalamin has improved bioavailability due to Hydrophilic - lipophilic mechanism allow it to reaches to target site for activation via microvilli into systemic pathway.

BBC is an initiative of Karnataka Innovation and Technology Society (KITS), Department of Electronics, Information Technology, Biotechnology, Science and Technology, Government of Karnataka and Department of Biotechnology, Government of India. 

Bangalore-based Stabicon, which is incubated at Bangalore Bioinnoavtion Centre (BBC), has launched CD4 Shield. The start-up has been working on prevention program for the novel coronavirus (nCOV-19) using the company’s proprietary Zuicel technology.